Edition:
United Kingdom

XOMA Corp (XOMA.OQ)

XOMA.OQ on NASDAQ Stock Exchange Global Market

16.12USD
6:19pm BST
Change (% chg)

$-0.08 (-0.49%)
Prev Close
$16.20
Open
$16.18
Day's High
$16.76
Day's Low
$15.96
Volume
5,913
Avg. Vol
39,548
52-wk High
$37.25
52-wk Low
$15.39

Chart for

About

XOMA Corporation is a development-stage biotechnology company. The Company focuses on the discovery and development of monoclonal antibody-based therapeutics. It has five products in its endocrine portfolio, two of which are developed as part of its XOMA Metabolism (XMet) platform. Its products include XOMA 358, XOMA 129, XOMA... (more)

Overall

Beta: 3.07
Market Cap(Mil.): $161.31
Shares Outstanding(Mil.): 7.60
Dividend: --
Yield (%): --

Financials

  XOMA.OQ Industry Sector
P/E (TTM): -- 85.68 32.76
EPS (TTM): -7.13 -- --
ROI: -481.50 1.78 14.61
ROE: -- 3.29 16.33

BRIEF-XOMA Reports Qtrly Loss Per Share $0.46

* QTRLY LOSS PER SHARE $0.46 Source text for Eikon: Further company coverage:

09 May 2018

BRIEF-Xoma Corp - Entered Loan And Security Agreement Of Up To $20.0 Million

* XOMA CORP - CO, UNITS ENTERED LOAN AND SECURITY AGREEMENT UNDER WHICH LENDER AGREED TO LEND UP TO $20.0 MILLION IN A SERIES OF TERM LOANS - SEC FILING

08 May 2018

BRIEF-Xoma Announces $20 Mln Credit Facility With Silicon Valley Bank To Advance Royalty-Aggregator Business Model

* XOMA ANNOUNCES $20 MILLION CREDIT FACILITY WITH SILICON VALLEY BANK TO ADVANCE ROYALTY-AGGREGATOR BUSINESS MODEL Source text for Eikon:

08 May 2018

BRIEF-Xoma Corp Says Amended License And Purchase Agreement Entered With Rezolute In Dec 2017

* XOMA CORP SAYS ON MARCH 30, CO AMENDED LICENSE AGREEMENT AND PURCHASE AGREEMENT ENTERED INTO WITH REZOLUTE IN DEC 2017 - SEC FILING Source text: (https://bit.ly/2GCCEuu) Further company coverage:

05 Apr 2018

Competitors

  Price Chg
Albireo Pharma Inc (ALBO.OQ) $33.49 +0.63

Earnings vs. Estimates